CA2304274A1 - Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies - Google Patents

Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies Download PDF

Info

Publication number
CA2304274A1
CA2304274A1 CA002304274A CA2304274A CA2304274A1 CA 2304274 A1 CA2304274 A1 CA 2304274A1 CA 002304274 A CA002304274 A CA 002304274A CA 2304274 A CA2304274 A CA 2304274A CA 2304274 A1 CA2304274 A1 CA 2304274A1
Authority
CA
Canada
Prior art keywords
chain
carbon atoms
straight
phenyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002304274A
Other languages
English (en)
Inventor
Michael Logers
Arndt Brandes
Gunter Schmidt
Jurgen Stoltefuss
Klaus-Dieter Bremm
Hilmar Bischoff
Delf Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2304274A1 publication Critical patent/CA2304274A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/46—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts
    • C07C33/48—Halogenated unsaturated alcohols containing only six-membered aromatic rings as cyclic parts with unsaturation outside the aromatic rings
    • C07C33/486—Polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C33/00—Unsaturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
    • C07C33/40—Halogenated unsaturated alcohols
    • C07C33/50—Halogenated unsaturated alcohols containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
    • C07C43/14—Unsaturated ethers
    • C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
    • C07C43/1786—Unsaturated ethers containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
    • C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

L'invention concerne des benzylbiphényles et des composés analogues, produit selon un procédé consistant tout d'abord à faire réagir des cétones .alpha. et .beta. insaturées pour former des diènes conjugués, substitués de façon correspondante, puis à cycliser ces derniers avec des dérivés d'acétylène, à oxyder les cyclohexanediènes ainsi obtenus pour former des composés aromatiques, et le cas échéant à les faire varier dans les substituants présents, selon des méthodes usuelles. Les composés de l'invention s'utilisent comme principes actifs dans des médicaments, notamment dans des médicaments servant à traiter l'artériosclérose et les dyslipidémies.
CA002304274A 1997-09-19 1998-09-09 Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies Abandoned CA2304274A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19741400.1 1997-09-19
DE19741400A DE19741400A1 (de) 1997-09-19 1997-09-19 Benzyl-biphenyle
PCT/EP1998/005731 WO1999015487A1 (fr) 1997-09-19 1998-09-09 Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies

Publications (1)

Publication Number Publication Date
CA2304274A1 true CA2304274A1 (fr) 1999-04-01

Family

ID=7842955

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002304274A Abandoned CA2304274A1 (fr) 1997-09-19 1998-09-09 Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies

Country Status (6)

Country Link
EP (1) EP1017658A1 (fr)
JP (1) JP2001517646A (fr)
AU (1) AU1145899A (fr)
CA (1) CA2304274A1 (fr)
DE (1) DE19741400A1 (fr)
WO (1) WO1999015487A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102304096A (zh) * 2004-07-02 2012-01-04 默沙东公司 Cetp抑制剂
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60122939T2 (de) * 2000-12-21 2007-01-11 Nitromed, Inc., Bedford Substituierte arylverbindungen als neue, cyclooxygenase-2-selektive inhibitoren, zusammensetzungen und verwendungsverfahren
JP2004534812A (ja) 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
OA12625A (en) 2001-06-22 2006-06-12 Pfizer Prod Inc Pharmaceutical compositions of adsorbates of amorphous drug.
DE60320940D1 (de) 2002-02-01 2008-06-26 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
BRPI0413277A (pt) 2003-08-04 2006-10-10 Pfizer Prod Inc composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2006082518A1 (fr) 2005-02-03 2006-08-10 Pfizer Products Inc. Compositions pharmaceutiques a efficacite amelioree
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
WO2007081570A2 (fr) * 2005-12-30 2007-07-19 Merck & Co., Inc. Inhibiteurs de proteine de transfert des esters de cholesterol
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
KR102651062B1 (ko) * 2020-10-08 2024-03-25 재단법인 대구경북첨단의료산업진흥재단 Pcsk9 억제제로서 아미노알콜 유도체 및 이를 함유하는 고콜레스테롤 혈증의 예방 또는 치료용 약학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169857A (en) * 1988-01-20 1992-12-08 Bayer Aktiengesellschaft 7-(polysubstituted pyridyl)-hept-6-endates useful for treating hyperproteinaemia, lipoproteinaemia or arteriosclerosis
DE3909378A1 (de) * 1989-03-22 1990-09-27 Bayer Ag Substituierte biphenyle
DE19704244A1 (de) * 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102304096A (zh) * 2004-07-02 2012-01-04 默沙东公司 Cetp抑制剂
CN102311401A (zh) * 2004-07-02 2012-01-11 默沙东公司 Cetp抑制剂
CN102304096B (zh) * 2004-07-02 2014-12-03 默沙东公司 Cetp抑制剂
CN102311401B (zh) * 2004-07-02 2014-12-03 默沙东公司 Cetp抑制剂
CN104557757A (zh) * 2004-07-02 2015-04-29 默沙东公司 Cetp抑制剂
US11078192B2 (en) 2016-07-05 2021-08-03 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
US11384048B2 (en) 2017-12-29 2022-07-12 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application

Also Published As

Publication number Publication date
DE19741400A1 (de) 1999-03-25
JP2001517646A (ja) 2001-10-09
EP1017658A1 (fr) 2000-07-12
AU1145899A (en) 1999-04-12
WO1999015487A1 (fr) 1999-04-01

Similar Documents

Publication Publication Date Title
US6387929B1 (en) 4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein
CA2209825C (fr) Pyridines avec condensation heterocyclique
CA2209640C (fr) Cycloalcanopyridines
US6586613B1 (en) Substituted tetrahydronaphthaline and analogous compounds
US6291477B1 (en) Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia
JP3157882B2 (ja) 新規なベンゾチオフエン誘導体
CA2304274A1 (fr) Benzylbiphenyles et composes analogues et leur utilisation pour le traitement de l'arteriosclerose et des dyslipidemies
US6063788A (en) Bicyclic-fused pyridines
CA2200175A1 (fr) Derives de substitution 2-aryliques de pyridines
US6207671B1 (en) Cycloalkano-pyridines
US4916148A (en) Naphtho(2,1-b) furan derivatives
AU682947B2 (en) Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity
US6121330A (en) 5-Hydroxyalkyl substituted phenyls and their use in medicaments for the treatment of arteriosclerosis and hyperlipoproteinaemia
EP0540400A1 (fr) Dérivés de quinoléine, utile comme angiotensine II antagonistes
AU730109B2 (en) 2-amino-substituted pyridines which can be used for the treatment of arteriosclerosis and hyperclipoproteinaemia
FI76071C (fi) Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(hydroxifenyl)indolderivat.
NZ243687A (en) 1-(omega-carboxyalkyl)-3-[3 or 4-(1-phenylalkoxy or 1-phenoxyalkyl)benzoyl]indole derivatives having steroid 5alpha-reductase inhibitory activity and medicaments
JP2005508341A (ja) ３−ヒドロキシ−（４−トリフルオロメチルフェニル）−メチル−７−スピロシクロブチル−５，６，７，８−テトラヒドロキノリン−５−オール誘導体およびコレステロールエステル転送タンパク質（ｃｅｔｐ）阻害剤としてのその使用
AU3497793A (en) Indole derivatives as steroid 5 alpha-reductase inhibitors
MXPA00002771A (en) Benzyl-biphenyls and analogous compounds and the application thereof in order to treat arteriosclerosis and dyslipidaemia
MXPA97002042A (en) Pyridine replaced by 2-ar
IL139706A (en) 3-amino-3-cyclopentyl-1-(4-trifluoromethyl phenyl)-propenone and its derivatives
MXPA99007244A (en) 2-amino substituted pyridines for use in the treatment of arteriosclerosis and hyperlipoproteinaemia

Legal Events

Date Code Title Description
FZDE Dead